Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences Raises $25.6M in Series A Financing

NEW YORK (GenomeWeb) – Precision BioSciences today announced it has closed a $25.6 million Series A financing round.

Life sciences investor VenBio led the round, joined by Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two unnamed public market investors.

"This financing will allow us to expand beyond our successful efforts to develop the leading next-gen genome editing platform and significantly accelerate the development of our genome-edited product pipeline," Precision BioSciences CEO Matthew Kane said in a statement.

Precision BioSciences' Arcus genome editing platform can remove, insert, and modify DNA at any location in the genome, the firm said in a statement, combining the target site flexibility of CRISPR/Cas9 along with the site specificity of homing endonucleases.

The Research Triangle Park, North Carolina-based company has signed collaborations to use its genome engineering platform in castor plants and corn.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.